CEO Robert Eno is departing the company effective June 30, 2026, as part of a strategic reorganization. Founder and President Dr. Branislav Vajdic and Executive Chairman Rich Ferrari will lead the company's new focused implementation teams. The company is pivoting from direct medical device sales to a licensing model for its 3D ECG signal technology. The strategy aims to reduce costs and accelerate global adoption by partnering with OEMs, health systems, and wearable manufacturers. The company continues to pursue FDA clearance for heart attack detection, expanding beyond its current arrhythmia assessment indication.